Literature DB >> 29285202

Effective treatment of a patient with stage IV ovarian cancer: A case report.

Zhen Huang1, Hua Yan2, Devendra Chavan1, Zeng Yuan1, Xingsheng Yang1, Youzhong Zhang1, Kun Song1, Beihua Kong1.   

Abstract

The present case report describes a patient with stage IV ovarian cancer who survived for 9 years without achieving a complete remission since the first relapse. The patient's long-term survival may be ascribed to the slow growth of the cancer cells, limited metastasis and favorable responses to the treatments received. The patient manifested initially with malignant pleural effusion and was not able to tolerate surgical treatment. However, the disease was well-controlled using various treatments, including neoadjuvant chemotherapy, interval cytoreductive surgery and post-operative long-term chemotherapy. Management of ovarian cancer is most effective when tailored to the individual needs of the patient, maximizing its efficacy and prolonging the patient's survival rate. The present case may offer useful insight into the clinical management of stage IV ovarian cancer.

Entities:  

Keywords:  interval cytoreductive surgery; neoadjuvant chemotherapy; ovarian neoplasms; post-surgery chemotherapy; treatment

Year:  2017        PMID: 29285202      PMCID: PMC5738686          DOI: 10.3892/ol.2017.7285

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  11 in total

Review 1.  Ovarian cancer.

Authors:  Gordon C Jayson; Elise C Kohn; Henry C Kitchener; Jonathan A Ledermann
Journal:  Lancet       Date:  2014-04-21       Impact factor: 79.321

2.  Secondary surgical cytoreduction for advanced ovarian carcinoma.

Authors:  Peter G Rose; Stacy Nerenstone; Mark F Brady; Daniel Clarke-Pearson; George Olt; Stephen C Rubin; David H Moore; James M Small
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

4.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors:  M E van der Burg; M van Lent; M Buyse; A Kobierska; N Colombo; G Favalli; A J Lacave; M Nardi; J Renard; S Pecorelli
Journal:  N Engl J Med       Date:  1995-03-09       Impact factor: 91.245

5.  Intervention debulking surgery in advanced epithelial ovarian cancer.

Authors:  C W Redman; J Warwick; D M Luesley; R Varma; F G Lawton; G R Blackledge
Journal:  Br J Obstet Gynaecol       Date:  1994-02

Review 6.  Can advanced-stage ovarian cancer be cured?

Authors:  Steven Narod
Journal:  Nat Rev Clin Oncol       Date:  2016-01-20       Impact factor: 66.675

Review 7.  Ovarian cancer: diagnostic, biological and prognostic aspects.

Authors:  Ben Davidson; Claes G Tropé
Journal:  Womens Health (Lond)       Date:  2014-09

Review 8.  Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.

Authors:  Nicoletta Colombo
Journal:  Int J Gynecol Cancer       Date:  2011-05       Impact factor: 3.437

9.  Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.

Authors:  S B Kaye; N Colombo; B J Monk; S Tjulandin; B Kong; M Roy; S Chan; E Filipczyk-Cisarz; H Hagberg; I Vergote; C Lebedinsky; T Parekh; P Santabárbara; Y C Park; A Nieto; A Poveda
Journal:  Ann Oncol       Date:  2010-07-19       Impact factor: 32.976

10.  Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.

Authors:  A Poveda; I Vergote; S Tjulandin; B Kong; M Roy; S Chan; E Filipczyk-Cisarz; H Hagberg; S B Kaye; N Colombo; C Lebedinsky; T Parekh; J Gómez; Y C Park; V Alfaro; B J Monk
Journal:  Ann Oncol       Date:  2010-07-19       Impact factor: 32.976

View more
  2 in total

1.  Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.

Authors:  Smrithi Padmakumar; Neha N Parayath; Shantikumar V Nair; Deepthy Menon; Mansoor M Amiji
Journal:  J Control Release       Date:  2019-05-17       Impact factor: 9.776

2.  Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.

Authors:  Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan
Journal:  Adv Ther (Weinh)       Date:  2020-08-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.